31/03/2008
In-vivo study shows ReGen’s ColostrininTM to be non-allergenic and able to prevent allergic inflammation.
ReGen Therapeutics Plc (‘ReGen’) is pleased to announce a report of a study conducted by Dr Istvan Boldogh* of the University of Texas Medical Branch was published on the 27 March on line in the International Archives of Allergy and Immunology. This study shows that ColostrininTM , ReGen’s nutraceutical product, being marketed by Metagenics Inc., California for the ‘support of healthy brain ageing and cognition’, is not only non-allergenic, but prevents allergic inflammation due to common indoor and outdoor allergens.
Currently Metagenics and or its subsidiaries are selling ColostrininTM in Australasia since July 2007 and North America since October 2007. Headquartered in San Clemente, California, Metagenics is a leading developer, manufacturer and marketer of nutraceuticals, dedicated to researching and evaluating the effects of natural ingredients on genetic expression and protein activity. Additionally, on 25 March 2008 ReGen announced its first approval to launch in the European Union in Cyprus through Golgi Pharmaceuticals Ltd its distributor for that market.
Highlights of the study are as follows:
The objective of the study was to investigate potential allergic responses to ColostrininTM and its impact on allergic sensitisation and inflammation caused by common allergens to underpin its safe use as a human nutraceutical . A spray-dried whole Colostrum product which is commercially available as a nutraceutical was used as a control
The study used a well characterised mouse model of allergic airway inflammation
ColostrininTM (given orally, intranasally or intraperitoneally) significantly decreased IgE/IgG1 production, airway eosinophilia, mucin production and hypersensitivity induced by allergenic extracts from ragweed pollen and house dust mites
In contrast, Colostrum, from which ColostrininTM is derived, induced positive inflammatory responses
Commenting on these findings Dr. Marian Kruzel (a co-author of the publication and a scientific advisor to ReGen) said: ‘ These findings are entirely consistent with Colostrinin’sTM safety profile and use to support healthy cognition through significant reduction of reactive oxygen species (ROS) build up.’
Percy Lomax, Chairman and Chief Executive Officer added: ‘The data shows that ColostrininTM may be used in humans without concern about experiencing an allergic reaction. This is in contrast to other less refined dairy-derived products, in particular whole colostrum, which is a significant US dietary product. We believe these findings will give impetus to the marketing of ColostrininTM.
Notes:
*To read the full report please go to http://www.karger.com and search for the International Archives of Allergy and Immunology 2008;146:298-306. This study was conducted by Dr Istvan Boldogh at the University of Texas Medical Branch, Galveston, Texas, USA. ReGen has a sponsored research agreement with the University of Texas Medical Branch, Galveston, Texas, USA.
A complete copy of the paper will be added to the ReGen website (http://www.regentherapeutics.com/) soon.
For further information, please contact:
Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel: 020 7628 3396